|Day's Range||1.35 - 1.44|
|52 Week Range||1.03 - 2.04|
|PE Ratio (TTM)||-6.90|
|Earnings Date||May 12, 2017 - May 15, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||5.30|
On a per-share basis, the West Haven, Connecticut-based company said it had a loss of 5 cents. The company's shares closed at $1.24. A year ago, they were trading at $1.55. _____ This story was generated ...
SHELTON, Conn., May 16, 2017 /PRNewswire/ -- NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company"), filed the quarterly report for its third quarter of financial year 2017 in a timely manner with the Securities and Exchange Commission on Monday, May 15th. NanoViricides reported that it had approximately $16.74 Million (M) of current assets (cash, cash equivalents, and prepaid expenses) as of March 31, 2017, the end of the reporting period. Briefly, holders of $5,000,000 principal value Series B Convertible Debentures, namely, an entity controlled by Dr. Milton Boniuk, a director of the Company, and The Boniuk Charitable Foundation, converted $5,000,000 of Series B debentures into equity, and the remaining $1,000,000 principal, with accrued interest as of the maturity date, was repaid to the holders thereof in cash, on or about.
SHELTON, Conn., April 26, 2017 /PRNewswire/ -- NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company"), reports that Eugene Seymour, MD, MPH, CEO, will present information about the Company and its progress towards human trials at the Planet Microcap conference at the Planet Hollywood Hotel. NanoViricides, Inc. is a global leader developing antiviral nanomedicines for the treatment of a number of different viral infections. The Company is currently focused on developing its broad spectrum anti-herpesvirus drug candidates.